<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/CE562D3D-45D5-45B3-99FF-A81611187A1C"><gtr:id>CE562D3D-45D5-45B3-99FF-A81611187A1C</gtr:id><gtr:name>Veterinary Services</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Psychiatry</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/CE562D3D-45D5-45B3-99FF-A81611187A1C"><gtr:id>CE562D3D-45D5-45B3-99FF-A81611187A1C</gtr:id><gtr:name>Veterinary Services</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/644B1691-6A0E-4FA0-A337-637808970B34"><gtr:id>644B1691-6A0E-4FA0-A337-637808970B34</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:otherNames>David</gtr:otherNames><gtr:surname>Rogers</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/DDD240F0-BF92-43B0-A7BA-57217BB59E46"><gtr:id>DDD240F0-BF92-43B0-A7BA-57217BB59E46</gtr:id><gtr:firstName>Trevor</gtr:firstName><gtr:surname>Sharp</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/0B7BA49E-A505-41DC-AB71-A59E5DEB972E"><gtr:id>0B7BA49E-A505-41DC-AB71-A59E5DEB972E</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Grasby</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8CB2FBAC-797E-4A4C-9B42-3B343A0266D6"><gtr:id>8CB2FBAC-797E-4A4C-9B42-3B343A0266D6</gtr:id><gtr:firstName>Guy</gtr:firstName><gtr:surname>Goodwin</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/382F3EEB-8130-4EB4-9046-EC4190AD6E07"><gtr:id>382F3EEB-8130-4EB4-9046-EC4190AD6E07</gtr:id><gtr:firstName>Philip</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Cowen</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/19D1396C-ECFC-4111-9838-02133E0C97EF"><gtr:id>19D1396C-ECFC-4111-9838-02133E0C97EF</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Harrison</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C50EE9C0-A0E3-4EB0-9EFD-C424F4204D12"><gtr:id>C50EE9C0-A0E3-4EB0-9EFD-C424F4204D12</gtr:id><gtr:firstName>Catherine</gtr:firstName><gtr:surname>Harmer</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/AB9A1DD7-6E64-4042-9440-5CA9F064300A"><gtr:id>AB9A1DD7-6E64-4042-9440-5CA9F064300A</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Richard</gtr:otherNames><gtr:surname>Geddes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G9900922"><gtr:id>53E8B502-3F7A-402A-873A-EBCB73E68352</gtr:id><gtr:title>The Neurobiology of Mood Disorders</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G9900922</gtr:grantReference><gtr:abstractText>Depression and bipolar disorder are clinical disturbances of mood, which are common and serious conditions. The medical importance of mood disorders is often underestimated but the World Health Organisation has predicted that depression will be the second most important cause of disability worldwide by 2020. This global burden emphasises not only the frequency of mood disorders but also their under-treatment, their recurrent nature and the high risk of suicide. All these factors highlight the need for more effective and acceptable treatments and so one of the aims of our Group is directly to develop and evaluate therapies for mood disorder. However discovering better treatment really requires a greater understanding of the nature of mood disorders. Therefore another key aim of the Group is to use a wide range of state-of- the-art methods to investigate what goes wrong in the brain in depression and what changes when antidepressant treatments are used. Such research can help discover not only the best targets for treatment but also the factors that lead to the disorder in the first place and that might be amenable to preventative measures. Our group brings together researchers with a special interest in mood disorders with the aim of using our combined expertise (which ranges from experimental studies in animals to brain imaging in patients and clinical trials) to design and carry out research projects that would be difficult for any of us to perform working alone. In the present grant we will make particular use of new techniques of magnetic brain imaging to learn more about the brain circuits that regulate emotional experience and the way in which they are modified by clinical mood disorders and their treatment.</gtr:abstractText><gtr:technicalSummary>Mood disorders are common and associated with very considerable morbidity and excess mortality. At present they are only poorly understood and partially treatable. The overarching objective of the Co-operative Group is to integrate clinical and laboratory neurobiological research to better understand the pathophysiology of mood disorders and thereby improve treatment and prognosis. The present application for renewed Co-operative status aims to build on the progress achieved during the tenure of our previous Co-operative Group, particularly in the integration of psychopharmacology with neuropsychological models of emotional processing. This has led to new ways of thinking about the psychological mechanisms that translate changes in the activity of relevant brain circuitry into clinical symptomatology and the therapeutic effects of psychotropic drugs. Our aim in the present Co-operative is to make full use of University facilities for functional magnetic resonance imaging to identify the neural substrates involved in these critical psychobiological interactions. As before our Co-operative will allow us to continue the vertical integration of our individual research efforts which range from molecular studies in animal and human tissue through PET imaging of molecular targets in patients, to growing expertise in clinical trials methodology. A particularly interesting finding derived from our previous Co-operative is the persistence of relevant neurobiological abnormalities in patients fully recovered from mood disorder and withdrawn from medication. We now have evidence of similar abnormalities in subjects who are at high risk of depression but who have not been depressed themselves. These abnormalities could represent an exciting opportunity to identify those at risk of mood disorder as well providing targets for preventative pharmacological or psychological treatment strategies. The ultimate aim of the Co-operative group therefore will be to use our growing knowledge of the neurobiology of depression and its treatment to provide realistic and effective preventative strategies for those at risk of recurrent mood disorder with its attendant personal and economic burdens.</gtr:technicalSummary><gtr:fund><gtr:end>2009-12-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2000-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>654010</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Sciences Division</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Pharmacology</gtr:department><gtr:description>Pharmacology</gtr:description><gtr:id>5A226A0A-1B86-4B42-A03B-AE1D53A3BD26</gtr:id><gtr:impact>Grant from BBSRC</gtr:impact><gtr:partnerContribution>basic animal studies which act as platform for human work.</gtr:partnerContribution><gtr:piContribution>Collaboration on clinical translation of a lithium-mimetic</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Newspaper interviews and reports</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>78CD3409-DEC3-4B73-94C8-0110D6DAE759</gtr:id><gtr:impact>Catherine Harmer gave interviews to newspapers about her work on emotional processing and antidepressants

Further articles in the press</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>360000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Strategic Research Grant</gtr:description><gtr:end>2012-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>3D30B5F1-181A-435D-93E7-D0A4D1E8B205</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>350000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Strategic Research Grant</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>07A43042-11DD-4E4E-A8F7-4FC656BEB97C</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A psychological test battery for the detection of psychotropically active drugs</gtr:description><gtr:id>35DF77B1-54FD-4BFF-AAE8-B4F199FA55A4</gtr:id><gtr:impact>Industrial support including funding</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:protection>Copyrighted (e.g. software)</gtr:protection><gtr:title>Emotional Test Battery</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NICE Panel on GAD</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>457A7DDA-8311-458A-B1D9-F2115A66BFCB</gtr:id><gtr:impact>An evidence-based guideline on the treatment of generalised anxiety disorder. Improvements in clinical practice and management.</gtr:impact><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>BAP guideline on bipolar disorder</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>69B6CE77-CF42-435A-8AB5-96F457C1D703</gtr:id><gtr:impact>Improvement in the pharmacological management of bipolar disorder at a national level</gtr:impact><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MRC strategic review on Mental Health Research</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>635633AA-DF92-43CA-8B36-C1B6DD0EC1C1</gtr:id><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Antioxidant drug repurposed as lithium mimetic</gtr:description><gtr:id>1E92A337-DD41-4D1B-BF72-23153F10B49B</gtr:id><gtr:impact>Principle of drug repurposing for psychiatry. basic to clinical collaboration. New drug development for area of great unmet clinical need.</gtr:impact><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Ebselen</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>P1Vital</gtr:companyName><gtr:description>Interface between Oxford University Dept of Psychiatry and Pharmaceutical Industry. Applying novel methods of drug discovery to screen for new antidperessants at phase 1-2; http://www.p1vital.com/</gtr:description><gtr:id>94F92957-7D7D-4B46-AFE4-885D71839449</gtr:id><gtr:impact>Income generation from Industry through take up of screening studies</gtr:impact><gtr:url>http://www.p1vital.com</gtr:url><gtr:yearCompanyFormed>2006</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6A8BA07B-0236-4BE1-A7E7-3BA0026A0D1D"><gtr:id>6A8BA07B-0236-4BE1-A7E7-3BA0026A0D1D</gtr:id><gtr:title>A cognitive neuropsychological model of antidepressant drug action.</gtr:title><gtr:parentPublicationTitle>Progress in neuro-psychopharmacology &amp; biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6aeda73005ba3b506f69f4a60f8cc0ca"><gtr:id>6aeda73005ba3b506f69f4a60f8cc0ca</gtr:id><gtr:otherNames>Pringle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0278-5846</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A5237662-8CE4-4F7A-B1B9-6620127A3911"><gtr:id>A5237662-8CE4-4F7A-B1B9-6620127A3911</gtr:id><gtr:title>NK1 receptor antagonism and emotional processing in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f2d5c7b9698c9414404e8f93f736b37c"><gtr:id>f2d5c7b9698c9414404e8f93f736b37c</gtr:id><gtr:otherNames>Chandra P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7CC6488F-BF9C-47D8-B731-60D04BA7C4FF"><gtr:id>7CC6488F-BF9C-47D8-B731-60D04BA7C4FF</gtr:id><gtr:title>Early effects of mirtazapine on emotional processing.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5df8850a1f0a1e49d2c0f76d0778101d"><gtr:id>5df8850a1f0a1e49d2c0f76d0778101d</gtr:id><gtr:otherNames>Arnone D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/91293C04-4B43-4B07-81A5-9DC57A890E72"><gtr:id>91293C04-4B43-4B07-81A5-9DC57A890E72</gtr:id><gtr:title>Single dose antidepressant administration modulates the neural processing of self-referent personality trait words.</gtr:title><gtr:parentPublicationTitle>NeuroImage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/33b6ce983acf43deeebe8ea421654844"><gtr:id>33b6ce983acf43deeebe8ea421654844</gtr:id><gtr:otherNames>Miskowiak K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1053-8119</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/10F5DDE7-F168-438B-B9B1-805A58D3CC68"><gtr:id>10F5DDE7-F168-438B-B9B1-805A58D3CC68</gtr:id><gtr:title>Dissociable effects of acute antidepressant drug administration on subjective and emotional processing measures in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9714622cbdf3aade07f0e4b795152598"><gtr:id>9714622cbdf3aade07f0e4b795152598</gtr:id><gtr:otherNames>Harmer CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6CBA8028-B8BF-471F-AAD7-93E9E20BA04E"><gtr:id>6CBA8028-B8BF-471F-AAD7-93E9E20BA04E</gtr:id><gtr:title>The role of serotonin in nonnormative risky choice: the effects of tryptophan supplements on the &amp;quot;reflection effect&amp;quot; in healthy adult volunteers.</gtr:title><gtr:parentPublicationTitle>Journal of cognitive neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4c2a8c889869049188f716ea80809693"><gtr:id>4c2a8c889869049188f716ea80809693</gtr:id><gtr:otherNames>Murphy SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0898-929X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F1CAC226-C477-49D2-9972-021DC8F8C069"><gtr:id>F1CAC226-C477-49D2-9972-021DC8F8C069</gtr:id><gtr:title>Oxytocin enhances processing of positive versus negative emotional information in healthy male volunteers.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3e9182640a623f56707624b00a3d534b"><gtr:id>3e9182640a623f56707624b00a3d534b</gtr:id><gtr:otherNames>Di Simplicio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DB3FD9D9-E25E-4735-9A35-0D8604F7EA62"><gtr:id>DB3FD9D9-E25E-4735-9A35-0D8604F7EA62</gtr:id><gtr:title>Increased neural response to fear in patients recovered from depression: a 3T functional magnetic resonance imaging study.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/66e098825713ff2a824ed36b33d241e9"><gtr:id>66e098825713ff2a824ed36b33d241e9</gtr:id><gtr:otherNames>Norbury R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6DB745FC-8A9A-463D-82D0-B3CF2AFCC88D"><gtr:id>6DB745FC-8A9A-463D-82D0-B3CF2AFCC88D</gtr:id><gtr:title>Using an experimental medicine model to understand the antidepressant potential of the N-Methyl-D-aspartic acid (NMDA) receptor antagonist memantine.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6aeda73005ba3b506f69f4a60f8cc0ca"><gtr:id>6aeda73005ba3b506f69f4a60f8cc0ca</gtr:id><gtr:otherNames>Pringle A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AB31EA39-DD40-4D9F-AEAF-39353CDCB605"><gtr:id>AB31EA39-DD40-4D9F-AEAF-39353CDCB605</gtr:id><gtr:title>Effects of alpha-lactalbumin on emotional processing in healthy women.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1ad6f6ea635bc308f88f6d140568c119"><gtr:id>1ad6f6ea635bc308f88f6d140568c119</gtr:id><gtr:otherNames>Scrutton H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/09FD6253-8F63-4C18-AF81-6207D7A6CF4C"><gtr:id>09FD6253-8F63-4C18-AF81-6207D7A6CF4C</gtr:id><gtr:title>NK1 receptor antagonism and the neural processing of emotional information in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>The international journal of neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4319dfcd8ef4be50b24fbceb03f6bfac"><gtr:id>4319dfcd8ef4be50b24fbceb03f6bfac</gtr:id><gtr:otherNames>McCabe C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1461-1457</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C7BF90CE-53E0-4D84-9CB6-221D0345514B"><gtr:id>C7BF90CE-53E0-4D84-9CB6-221D0345514B</gtr:id><gtr:title>Agomelatine facilitates positive versus negative affective processing in healthy volunteer models.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9714622cbdf3aade07f0e4b795152598"><gtr:id>9714622cbdf3aade07f0e4b795152598</gtr:id><gtr:otherNames>Harmer CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7FC39018-031D-45A8-AED7-B54E64118634"><gtr:id>7FC39018-031D-45A8-AED7-B54E64118634</gtr:id><gtr:title>Tryptophan supplementation induces a positive bias in the processing of emotional material in healthy female volunteers.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4c2a8c889869049188f716ea80809693"><gtr:id>4c2a8c889869049188f716ea80809693</gtr:id><gtr:otherNames>Murphy SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/18EDE11E-4361-482B-8638-01C536365A25"><gtr:id>18EDE11E-4361-482B-8638-01C536365A25</gtr:id><gtr:title>5-HT(1A) receptor binding in euthymic bipolar patients using positron emission tomography with [carbonyl-(11)C]WAY-100635.</gtr:title><gtr:parentPublicationTitle>Journal of affective disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/acff62a9e6a23524e818e2dcff89220d"><gtr:id>acff62a9e6a23524e818e2dcff89220d</gtr:id><gtr:otherNames>Sargent PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0165-0327</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7CC52C60-B0F2-4C51-BA8B-C986C1BBB3FC"><gtr:id>7CC52C60-B0F2-4C51-BA8B-C986C1BBB3FC</gtr:id><gtr:title>Short-term serotonergic but not noradrenergic antidepressant administration reduces attentional vigilance to threat in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>The international journal of neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4c2a8c889869049188f716ea80809693"><gtr:id>4c2a8c889869049188f716ea80809693</gtr:id><gtr:otherNames>Murphy SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1461-1457</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E38D59B0-EBA1-4C40-BEB4-9301A260175B"><gtr:id>E38D59B0-EBA1-4C40-BEB4-9301A260175B</gtr:id><gtr:title>Efficacy markers in depression.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9714622cbdf3aade07f0e4b795152598"><gtr:id>9714622cbdf3aade07f0e4b795152598</gtr:id><gtr:otherNames>Harmer CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B0E2631D-9630-4A84-A03C-770BA1905D28"><gtr:id>B0E2631D-9630-4A84-A03C-770BA1905D28</gtr:id><gtr:title>Direct effects of diazepam on emotional processing in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4c2a8c889869049188f716ea80809693"><gtr:id>4c2a8c889869049188f716ea80809693</gtr:id><gtr:otherNames>Murphy SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/64FB414C-0839-40B1-B4E7-389092F87331"><gtr:id>64FB414C-0839-40B1-B4E7-389092F87331</gtr:id><gtr:title>Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cc9a6a70cdcc515d2da40dad66f5d21a"><gtr:id>cc9a6a70cdcc515d2da40dad66f5d21a</gtr:id><gtr:otherNames>Horder J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/61A7B3C7-3D2D-41F3-A762-A8D7A2EEB0B6"><gtr:id>61A7B3C7-3D2D-41F3-A762-A8D7A2EEB0B6</gtr:id><gtr:title>Neural representation of reward in recovered depressed patients.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4319dfcd8ef4be50b24fbceb03f6bfac"><gtr:id>4319dfcd8ef4be50b24fbceb03f6bfac</gtr:id><gtr:otherNames>McCabe C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A857CB7B-E567-4AA1-A02D-3C6835F4E536"><gtr:id>A857CB7B-E567-4AA1-A02D-3C6835F4E536</gtr:id><gtr:title>Effect of a single dose of citalopram on amygdala response to emotional faces.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4c2a8c889869049188f716ea80809693"><gtr:id>4c2a8c889869049188f716ea80809693</gtr:id><gtr:otherNames>Murphy SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6DBFDC8B-9C08-4C6C-9C3D-4566E25F9335"><gtr:id>6DBFDC8B-9C08-4C6C-9C3D-4566E25F9335</gtr:id><gtr:title>A single dose of citalopram increases fear recognition in healthy subjects.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/703566a36c909175a74bbc59ec5b81a9"><gtr:id>703566a36c909175a74bbc59ec5b81a9</gtr:id><gtr:otherNames>Browning M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/749DE4ED-BD43-4611-A0B3-669F3C936F35"><gtr:id>749DE4ED-BD43-4611-A0B3-669F3C936F35</gtr:id><gtr:title>5HT(3) antagonism abolishes the emotion potentiated startle effect in humans.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9714622cbdf3aade07f0e4b795152598"><gtr:id>9714622cbdf3aade07f0e4b795152598</gtr:id><gtr:otherNames>Harmer CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/34C18E6B-8C08-4613-9342-90B233C983B1"><gtr:id>34C18E6B-8C08-4613-9342-90B233C983B1</gtr:id><gtr:title>High-density negative ion treatment increases positive affective memory.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5e3f7deeb40b8e819fef1f5f58025e16"><gtr:id>5e3f7deeb40b8e819fef1f5f58025e16</gtr:id><gtr:otherNames>Malcolm CP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D72B6749-0CA2-4D40-899F-7133D3A5457A"><gtr:id>D72B6749-0CA2-4D40-899F-7133D3A5457A</gtr:id><gtr:title>Negative ion treatment increases positive emotional processing in seasonal affective disorder.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9714622cbdf3aade07f0e4b795152598"><gtr:id>9714622cbdf3aade07f0e4b795152598</gtr:id><gtr:otherNames>Harmer CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G9900922</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>